Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.40 |
| ▸ | SLC2A1 | P11166 | 9/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | RAD52 | P43351 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3292083 | 0.79 | RAD52 (0.47) | CACNA2D1SLC2A1POLBRAD52NPC1 | |
| SCHEMBL3290733 | 0.74 | POLB (0.51) | SLC2A1POLBRAD52NPC1APOBEC3A | |
| SCHEMBL3298450 | 0.73 | KAT2B (0.44) | CACNA2D1SLC2A1POLBRAD52NPC1 | |
| SCHEMBL3427601 | 0.70 | EGFR (0.43) | SLC2A1 | |
| SCHEMBL3427605 | 0.70 | EGFR (0.43) | SLC2A1 | |
| SCHEMBL5811815 | 0.69 | TERT (0.40) | — | |
| SCHEMBL3291426 | 0.66 | BRD4 (0.46) | NPC1RAB9AKMT2AHRH3ACHE | |
| SCHEMBL8480481 | 0.65 | TERT (0.51) | POLBRAD52NPC1RAB9AKMT2A | |
| Biscryptolepine SCHEMBL30192568 | 0.65 | TERT (0.54) | POLBNPC1RAB9AKMT2A | |
| Iodide SCHEMBL8482236 | 0.64 | TERT (0.50) | POLBRAD52NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100331355-A1 | Substituted Quinolines for the Treatment of Cancer | CRYSTAX PHARMACEUTICALS, S.L. (ES) | 2010-12-30 | — | — | US | disclosed |
| US-20070105784-A1 | Substituted quinolines for the treatment of cancer | CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) | 2007-05-10 | — | — | US | disclosed |
| EP-1687304-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER | Crystax Pharmaceuticals S.L. (ES) | 2006-08-09 | — | — | EP | disclosed |
| WO-2005054236-A1 | SUBSTITUTED QUINOLINES FOR THE TREATMENT OF CANCER | CRYSTAX PHARMACEUTICALS S.L. (ES) | 2005-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070105784-A1 | Substituted quinolines for the treatment of cancer | TOP2B, NQO2, SNRPD2 | CACNA2D1 2429/4885SLC2A1 1392/4885POLB 599/4885 |
| US-20100331355-A1 | Substituted Quinolines for the Treatment of Cancer | TOP2B, TOP1, TOP2A | CACNA2D1 2362/4885SLC2A1 1045/4885POLB 607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.